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Kit and Melanocyte Migration
James M. Grichnik1,2
As described in this issue, Alexeev and Yoon introduced a Kit-activating muta-
tion into melanocytes. Although mitogenic in mast cells, this mutation was 
motogenic in melanocytes. Further, melanocytes had a reduced proliferative 
rate and were less differentiated. The disparate response may be due to differ-
ences in the cellular milieu of melanocytes and may have implications for nor-
mal melanocytic integration into the epidermis, nevogenesis, and melanoma.
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The receptor tyrosine kinase Kit is a criti-
cal regulatory molecule involved in the 
development and the homeostasis of 
several cell systems, including the hema-
tologic, mast, germ, and melanocytic 
cell systems. The regulation of the Kit 
pathway is complex. Expression of both 
the Kit receptor and its ligand stem cell 
factor is tightly regulated and occurs in 
waves during development and in intri-
cate homeostatic patterns in the adult. A 
number of isoforms are known for both 
the receptor and its ligand, and to fur-
ther complicate the picture, the ligand 
can interact with the receptor in both 
soluble and membrane-bound forms 
(Ronnstrand, 2004). Binding of the sol-
uble form leads to Kit receptor activa-
tion, internalization, and degradation, 
and binding of the membrane-bound 
form leads to a prolonged Kit-activated 
state. The Kit receptor has nine potential 
tyrosine phosphorylation sites, which 
interact with multiple downstream sig-
naling pathways (Ronnstrand, 2004). 
These signaling pathways include 
Ras–Erk, phosphatidylinositol 3-kinase 
(PI3K), phospholipase C-γ, the Src fam-
ily, and adapter proteins such as Grb2 
(Ronnstrand, 2004). Serine residues on 
the Kit receptor can also be phosphory-
lated and serve to modify Kit regulatory 
functions (Blume-Jensen et al., 1993). 
The ability of Kit to activate these dif-
ferent downstream pathways is clearly 
dependent on the presence and the 
activation state of multiple other cellu-
lar factors. Thus the Kit receptor cannot 
be viewed as a simple on/off switch 
and is best viewed as an inducible and 
malleable scaffold upon which mul-
tiple cellular regulatory mechanisms 
can be modulated.
In the melanocytic system, Kit plays 
a critical role in a number of cellular 
activities, including migration, survival, 
proliferation, and differentiation.
Migration
Patients with piebaldism have Kit 
receptor defects and clinically present 
at birth with amelanocytic patches of 
skin in a ventral/acral pattern. This pat-
tern suggests that the developing mela-
nocytes lack the capacity to migrate to 
those more distant locations from the 
neural crest. Similar patterns also exist 
in mice, and the role of Kit in murine 
development has been extensively 
studied. Kit activation has been shown 
to be required for melanocytic disper-
sal on the lateral pathway (Wehrle-
Haller and Weston, 1995). Discrete Kit-
sensitive and -resistant developmental 
stages have been defined (Yoshida et 
al., 1996). The defined Kit-dependent 
stages include migration in the dermis, 
proliferation in the epidermis, and inte-
gration into developing hair follicles. 
Although it is not possible to fully sepa-
rate the survival and proliferative effects 
of Kit, it is clear that Kit plays a major 
role in melanocytic migration.
Survival
Mice deficient in Kit activation present 
anemic, white, and sterile, reflecting 
the fact that Kit activation is required 
for the survival of these cell popula-
tions. As noted above, there are spe-
cific time points when melanocyte 
cells are Kit sensitive, and the timing 
of Kit inhibition results in different pat-
terns of melanocyte loss (Yoshida et al., 
1996). In the absence of Kit signaling, 
the Kit-sensitive cells undergo apop-
tosis (Ito et al., 1999). Kit inhibition 
also appears to drive melanocytic loss 
in human skin (Grichnik et al., 1998). 
In human skin xenografts, nevus cells 
have a reduced sensitivity to Kit inhibi-
tion as compared with epidermal mela-
nocytes (Grichnik et al., 2000), and a 
Kit-positive melanoma was found to be 
resistant (data not shown). Thus, Kit is a 
critical survival factor for melanocytic 
cells under certain environmental and 
developmental conditions.
Proliferation
Kit is also a proliferative factor. In 
transgenic mice the overexpression of 
the membrane-bound form of the Kit 
ligand in the epidermis results in mela-
nocytic hyperplasia (Kunisada et al., 
1998). Injection of the Kit ligand into 
human skin xenografts has revealed 
increases in cycling melanocytes and 
in cell number (Grichnik et al., 2000). 
In vitro, Kit activation has been shown 
to drive the proliferation of cells of the 
melanocytic lineage (Sviderskaya et al., 
1995). Levels of synergistic factors can 
alter the detectable effects of Kit activa-
tion on melanocytes. For example, in 
serum-free conditions, in the absence 
of basic fibroblast growth factor Kit 
activation promotes survival; in the 
presence of low levels of basic fibro-
blast growth factor Kit activation accel-
erates proliferation; but in the presence 
of high levels of  basic fibroblast growth 
factor no apparent effect of Kit activa-
tion can be detected (Lin et al., 2000.). 
Thus, Kit activation has the capacity to 
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drive proliferation in the appropriate 
cytokine environment.
Differentiation
In the presence of other factors, par-
ticularly endothelin-3, stem cell fac-
tor participates in driving melanocytic 
differentiation (Ono et al., 1998). 
However, unopposed Kit stimulation 
may promote the expansion of cells 
in a less differentiated state (Aoki et 
al., 2005; Ito et al., 2004; Sviderskaya 
et al., 1995). Thus, the differentiation 
capacity of Kit is dependent on other 
environmental signals.
In summary, Kit appears to play key 
roles in melanocyte migration, survival, 
proliferation, and differentiation, but 
these roles are modulated by other reg-
ulatory interactions.
In a study reported in this issue, 
Alexeev and Yoon (2006) introduced 
a Kit-activating mutation associated 
with mast-cell neoplasia (D814Y) into 
an immortalized murine melanocyte 
line (melan-c). This mutation resulted 
in the generation of an activated form 
of the Kit receptor that was shown to 
be phosphorylated on Tyr719. This site 
is associated with the ability to acti-
vate PI3K, and persistently increased 
levels of activated PI3K were demon-
strated. However, a downstream mol-
ecule for PI3K, AKT, was not found to 
be activated in these cells; this sug-
gests a difference between acutely 
activated and persistently activated 
Kit–PI3K pathways. Other Kit-activated 
signaling pathways were not specifi-
cally evaluated.
The major effect of the D814Y muta-
tion was to increase cell migration. The 
D814Y Kit-activated cells revealed a 
12-fold increased capacity to migrate 
across a porous membrane as com-
pared with the control cells. Further, 
this capacity was not limited to the in 
vitro environment but was also dem-
onstrated in vivo. Cells were injected 
into the hypodermis and deep dermis 
of BALB/c albino mice and followed 
for 12 weeks. At the end of this period, 
the control cells had failed to signi-
ficantly migrate, whereas the D814Y 
Kit-activated cells were noted to have 
migrated upward through the dermis 
and demonstrated insertion into the 
epidermis. Proliferation of the D814Y 
Kit-activated cells was noted to be 
decreased, with cell cycling times of 
32 hours compared with 27 hours for 
the control cells. The D814Y Kit-acti-
vated cells also appeared to exhibit a 
less differentiated state, with decreased 
melanin content, decreased tyrosinase 
protein, and a marked reduction of the 
56-kilodalton form of microphthalmia-
associated transcription factor. The 
cells were also noted to have a spin-
dle morphology and fewer dendrites. 
Dopachrome tautomerase and Pmel17 
levels were not appreciably altered. 
Regarding survival, no difference was 
specifically identified, but the amount 
of visible pigmentation suggested that 
the injected control cells may not have 
survived as well as the injected D814Y 
Kit-activated cells. Thus, overall, the 
D814Y mutation created melanocytic 
cells that were highly migratory but 
had a reduced proliferative rate and 
appeared somewhat less differentiated 
(with less melanin and tyrosinase and 
fewer dendrites).
One of the striking features of this 
work is that a mutation known to drive 
proliferation in mast cells instead drives 
migration in the melanocytes. This sug-
gests that the mutant Kit evokes a dif-
ferent balance of signaling pathways 
in the two different cell types. It is of 
interest that differences in mast-cell and 
melanocytic response have also been 
noted in the different Kit ligand iso-
forms. Transgenic mice expressing the 
membrane-bound form exhibit marked 
melanocytic hyperplasia, whereas mice 
expressing the soluble (cleavable) form 
exhibit a more exuberant mast-cell 
hyperplasia (Kunisada et al., 1998). It is 
possible that there are differences in the 
cellular milieu of melanocytes and mast 
cells that drive these different responses. 
Differences in protein kinase C path-
ways are worthy of consideration. The 
level of protein kinase C-mediated 
phosphorylation of Kit serine residues 
has been shown to switch downstream 
Kit activation pathways from mitogenic 
to motogenic in transfected endothelial 
cells (Blume-Jensen et al., 1993). If pro-
tein kinase C pathways are involved, 
then higher levels of activated protein 
kinase C isoforms in melanocytes may 
be blocking the mitogenic effect of the 
Kit mutant. It is possible that the Kit 
motogenic environment predominates 
over the Kit mitogenic environment in 
melanocytic cells, which may explain 
why activated Kit pathways have not yet 
been associated with melanoma.
Another striking feature of this work 
(Alexeev and Yoon, 2006) is the abil-
ity of the injected D814Y Kit cells to 
migrate through the dermis and insert 
into the epidermis. It is possible that the 
pathways followed by these cells mimic 
those normally followed during devel-
opment. This finding raises the ques-
tion of what mechanisms were used to 
attract these migration-primed cells to 
the epidermis. Although it is possible 
that stem cell factor binding in vivo 
still modulated the D814Y-activated Kit 
receptor through other regulatory mech-
anisms, it is likely that other cytokines 
or epidermal attractive mechanisms 
were at work. It is of interest that these 
D814Y-activated Kit melanocytes also 
expressed N-cadherin, which may be 
expressed on dermal melanocytic cells 
(Pla et al., 2001). This model should 
allow further studies on the mechanism 
of normal melanocytic integration into 
the epidermis. These findings may also 
have implications for nevogenesis and 
allow studies to explore the possibility 
that mutant dermal cells can give rise to 
melanocytic neoplasms with an epider-
mal component.
Thus the work of Alexeev and Yoon 
(2006) provides a window into the com-
plex regulatory roles of Kit. The D814Y 
Kit-activated mutation highlights the 
difference between cellular environ-
ments. In contrast to the mitogenic 
effect in mast cells, a motogenic effect 
was found in the melanocytic cells. It 
is possible that this motogenic effect 
can be converted to a mitogenic effect 
by alteration of other Kit-interacting 
pathways. However, if the motogenic 
environment is the default environment 
for melanocytes, then this may explain 
why no Kit-activating mutations have 
been identified in melanoma thus far, 
as opposed to the Kit-activated neopla-
sias identified for a number of other cell 
types (Longley et al., 2001). It may sim-
ply be too much of a hurdle to create 
the Kit mitogenic environment in mela-
noma, so it is possible that this problem 
is avoided in many melanomas simply 
by downregulation of Kit. In addition 
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to the insight this model will provide 
for melanoma, it should also provide 
insight into the complex control of 
melanocytic migration and possibly the 
development of nevi. Kit remains a criti-
cally important regulatory molecule in 
melanocytic biology.
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Functioning Methionine-S-Sulfoxide 
Reductases A and B Are Present in 
Human Skin
Karin U. Schallreuter1,2
Methionine residues in the structure of proteins and peptides are especially sensi-
tive to oxidation by hydrogen peroxide (H2O 2) yielding both the (R) and (S) dia-
stereomers of methionine sulfoxide. This commentary shows that both diastereo-
mers of methionine sulfoxide (R and S) can be repaired in the human epidermis by 
methionine sulfoxide reductases A and B, respectively.
Journal of Investigative Dermatology (2006) 126, 947–949. doi:10.1038/sj.jid.5700086
Several lines of evidence provide sup-
port for the concept that oxidative 
stress causes aging and limits lifespan. 
Therefore, one crucial question arises: 
how does the human epidermis combat 
major oxidative stress–induced protein 
alterations? In this issue, Ogawa et al. 
(2006) describe the discovery of epider-
mal methionine-S-sulfoxide reductase A 
(MSRA), which contributes significantly 
to the presence of oxidative stress repair 
mechanisms in the human skin. Since 
hydrogen peroxide (H2O2) can oxidize 
the sulfur-containing methionine and 
cysteine residues in protein sequences, 
leading to disruption of protein structure 
and, in turn, to dysfunction, this com-
mentary will put the specific problem 
of this reactive oxygen species (ROS)-
mediated damage to proteins and pep-
tides into the context of the repair mech-
anisms involving MSRA and methionine-
S-sulfoxide reductase B (MSRB), both of 
which are essential to salvaging of pro-
tein structure and function as well as to 
cell viability.
ROS oxidation of selective methionine, 
tryptophan, cysteine residues, and 
disulfide bridges in proteins and peptides
The epidermis is especially vulnerable to 
oxidative stress caused by multiple exog-
enous stimuli as well as by a plethora 
of endogenous metabolic events. Many 
mechanisms have been identified in 
controlling the maintenance of the redox 
balance in phase (Nordberg and Arner, 
2001; Schallreuter and Wood, 2001). As 
is pointed out by Ogawa et al. (2006) and 
in earlier work from the same group, skin 
aging is also associated with a decreased 
capacity to neutralize ROS and to repair 
damaged proteins as well as DNA (Thiele 
et al., 1999). In this context Shigenaga 
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